COMPUGEN LTD. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.955 USD | +1.82% |
|
+2.12% | -2.53% |
| 03-08 | Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating | MT |
| 03-05 | Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024 |
Chart calendar Compugen Ltd.
fde486499201bd019dbbb703f.uM6QOmQUNjYZpWXQOE-WeWw4ReUOGetllrm1KbrqnJs.6bjSZQAlUUxd4xKRT3ihGy1bDrBGKp4W8O-GU_bY7O_olvpPDiFGdVHhLA~1e16068a2f3dc492b18460cdfdb8336e
Upcoming events on Compugen Ltd.
Past events on Compugen Ltd.
| 15/04/2024 14:00 | CG Horizons in Oncology Virtual Conference |
| 10/04/2024 17:00 | American Association for Cancer Research Meeting - Abstract Number: 7533 |
| 10/04/2024 13:00 | Needham Healthcare Conference |
| 09/04/2024 17:00 | American Association for Cancer Research Meeting - Abstract Number: 4072 |
| 18/03/2024 | Keystone Symposium - Poster No: 2042 |
| 17/03/2024 | Keystone Symposium - Poster No: 1001 |
| 11/03/2024 15:20 | Leerink Partners Global Biopharma Conference |
| 05/03/2024 13:30 | Q4 2023 Earnings Call |
| 05/03/2024 12:00 | Q4 2023 Earnings Release |
| 19/12/2023 13:30 | Business Update Call |
| 07/11/2023 13:30 | Q3 2023 Earnings Call |
| 07/11/2023 12:00 | Q3 2023 Earnings Release |
| 03/11/2023 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 640 |
| 03/11/2023 22:30 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 550 |
| 02/11/2023 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 550 |
| 02/11/2023 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 669 |
| 02/11/2023 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 29 |
| 08/10/2023 | Single Cell Genomics Meeting - Poster Number: P1.65 |
| 11/09/2023 12:00 | H.C. Wainwright Global Investment Conference |
| 07/08/2023 13:30 | Q2 2023 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 2,00 0,00 - | 6,00 6,86 -12.5% | 7,50 0,00 - | 33,5 22,5 48.71% | 37,9 |
|
EBITDA Million USD | Released Forecast Spread | -27,9 -27,8 -0.32% | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -28,9 -28,8 -0.44% | -31,5 -31,2 -1.03% | -35,1 -37,8 7.13% | -35,4 -44,0 19.55% | -13,0 -40,2 67.66% | -15,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -28,1 -28,4 1.28% | -29,7 -29,6 -0.44% | -34,2 -36,8 7.14% | -33,6 -42,5 20.77% | -9,78 -37,7 74.04% | -13,3 |
|
Net income Million USD | Released Forecast Spread | -27,3 -27,9 2.08% | -29,7 -29,6 -0.39% | -34,2 -37,2 7.95% | -33,7 -42,8 21.24% | -18,8 -17,8 -5.53% | -13,4 |
|
EPS USD | Released Forecast Spread | -0,43 -0,44 2.27% | -0,37 -0,37 1.15% | -0,41 -0,44 7.12% | -0,39 -0,49 20.18% | -0,21 -0,20 -3.28% | -0,13 |
| Announcement Date | 20/02/20 | 25/02/21 | 24/02/22 | 27/02/23 | 05/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,86 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 7,50 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 2,50 - | 33,5 20,0 67.3% | 1,21 | 1,21 | 1,21 | 14,3 | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -8,78 -11,5 23.45% | -10,00 -10,3 3.25% | -9,64 -10,7 10.1% | -12,2 -11,0 -10.82% | -3,53 -12,1 70.93% | -10,1 -10,8 6.05% | -10,2 -10,9 6.7% | -10,6 -7,78 -36.69% | 18,0 -11,9 250.63% | -10,8 | -11,2 | -10,7 | 13,8 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -8,65 -11,3 23.27% | -9,71 -10,2 4.42% | -9,14 -10,8 15.51% | -11,7 -11,4 -3.49% | -3,03 -11,9 74.4% | -9,33 -10,2 8.66% | -9,33 -10,6 11.66% | -9,85 -7,32 -34.63% | 18,7 -11,6 261.87% | -10,1 | -9,93 | -9,62 | 14,7 | |
|
Net income Million USD | Released Forecast Spread | -8,65 -11,6 25.55% | -9,71 -10,4 6.77% | -9,14 -10,4 12.39% | -11,7 -11,0 -7% | -3,09 -12,2 74.61% | -9,34 -10,4 9.83% | -9,28 -10,8 14.04% | -9,85 -8,31 -18.53% | 9,71 9,09 6.85% | -10,1 | -9,93 | -9,62 | 14,5 | |
|
EPS USD | Released Forecast Spread | -0,10 -0,14 26.31% | -0,11 -0,13 12.5% | -0,11 -0,12 8.33% | -0,14 -0,13 -11.37% | -0,04 -0,14 72% | -0,11 -0,12 4.93% | -0,11 -0,13 12% | -0,11 -0,09 -17.86% | 0,11 0,10 6.46% | -0,11 | -0,11 | -0,11 | 0,15 | |
| Announcement Date | 24/02/22 | 16/05/22 | 04/08/22 | 14/11/22 | 27/02/23 | 15/05/23 | 07/08/23 | 07/11/23 | 05/03/24 | - | - | - | - | - |
| Today 21:05 | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 11:30 | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 11:30 | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 12:00 | ALKERMES PLC: Q1 2024 Earnings Release |
| 01/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Compugen Ltd.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CGEN Stock
- Calendar Compugen Ltd.
